Michael Gibson, CEO of Baim Institute for Clinical Research, shared a post on X:
“Regulators introduce framework allowing individualized therapies such as gene editing or RNA drugs to be approved with smaller datasets when traditional trials are impossible which could speed access for ultra‑rare conditions and shift safety monitoring to post‑approval studies.”
Other articles about RNA on OncoDaily.